C5AR1 and COVID-19: Although the complement action is not entirely clear about its protection or pathogenicity, a recent study proved the efficacy of a monoclonal antibody against C5/C5a, called eculizumab, in order to ameliorate the pulmonary dysfunction due to COVID-19 (90).